Next Article in Journal
Pricing and Reimbursement of Novel Oncology Drugs in Sweden
Previous Article in Journal
And If the Discovery of New Drugs for the Treatment of Brain Diseases Depends on Asian Countries?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 2
Issue 1
10.3402/jmahp.v2.22761
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

The Value of Quantitative Patient Preferences in Regulatory Benefit-Risk Assessment

by
Mart oude Egbrink
and
Maarten IJzerman
*
Department Health Technology and Services Research, School of Management and Governance, University of Twente, NL-7500 Enschede, The Netherlands
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2014, 2(1), 22761; https://doi.org/10.3402/jmahp.v2.22761
Submission received: 5 September 2013 / Revised: 3 February 2014 / Accepted: 10 February 2014 / Published: 1 April 2014

Abstract

Quantitative patient preferences are a method to involve patients in regulatory benefit-risk assessment. Assuming preferences can be elicited, there might be multiple advantages to their use. Legal, methodological and procedural issues do however imply that preferences are currently at most part of the solution on how to best involve patients in regulatory decision making. Progress is recently made on these issues.
Keywords: patient involvement; preferences; benefit-risk assessment; European Medicines Agency patient involvement; preferences; benefit-risk assessment; European Medicines Agency

Share and Cite

MDPI and ACS Style

Egbrink, M.o.; IJzerman, M. The Value of Quantitative Patient Preferences in Regulatory Benefit-Risk Assessment. J. Mark. Access Health Policy 2014, 2, 22761. https://doi.org/10.3402/jmahp.v2.22761

AMA Style

Egbrink Mo, IJzerman M. The Value of Quantitative Patient Preferences in Regulatory Benefit-Risk Assessment. Journal of Market Access & Health Policy. 2014; 2(1):22761. https://doi.org/10.3402/jmahp.v2.22761

Chicago/Turabian Style

Egbrink, Mart oude, and Maarten IJzerman. 2014. "The Value of Quantitative Patient Preferences in Regulatory Benefit-Risk Assessment" Journal of Market Access & Health Policy 2, no. 1: 22761. https://doi.org/10.3402/jmahp.v2.22761

APA Style

Egbrink, M. o., & IJzerman, M. (2014). The Value of Quantitative Patient Preferences in Regulatory Benefit-Risk Assessment. Journal of Market Access & Health Policy, 2(1), 22761. https://doi.org/10.3402/jmahp.v2.22761

Article Metrics

Back to TopTop